Video

Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate Cancer

Author(s):

Tian Zhang, MD, MHS, UT Southwestern Medical Center

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

The STAMPEDE trial compared abiraterone acetate (Zytiga) to androgen deprivation therapy (ADT) in patients with metastatic and nonmetastatic prostate cancer.

Early disease-free survival benefits are being seen with abiraterone acetate in the nonmetastatic setting, suggesting it could be a marker for overall survival benefit, says Zhang.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Guenther Koehne, MD, deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, Baptist Health South Florida
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Bradley McGregor, MD
Katherine L. Nathanson, MD
Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.
Related Content
2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib
March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

Oncology Unplugged With Dr Chandler Park
February 26th 2025

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

Casdatifan in ccRCC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 12th 2025

Casdatifan Monotherapy Shows Early Efficacy Signals and Tolerable Safety Profile in Pretreated ccRCC

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Cemiplimab Plus Chemotherapy in Advanced/Metastatic Penile Carcinoma | Image Credit: © Katsyarina – stock.adobe.com
March 11th 2025

Cemiplimab Plus Chemotherapy Yields Responses in Advanced/Metastatic Penile Carcinoma

Kidney Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 10th 2025

Latent Viruses in Human Genome Inspire Novel Directions for Kidney Cancer Immunotherapy